Home  /   Blog

  New ETAP-Lab studies on TEMISIS' drug candidate TEM1657 for Psoriasis   ETAP-Lab performed new studies for the account of TEMISIS on a mouse imiquimod-induced psoriasis model. The output of these studies showed that TEM1657 brings remarkable effects on psoriasis: Higher efficacy compared to the reference molecule No side effects Oral administration, which is new for the psoriasis treatment The French biotech company “Temesis”, subsidiary of Plant Advanced Technologies, recently published a new press release to announce these new promising preclinical results on psoriasis with

  ETAP-Lab supports Plant Advanced Technologies in the development of its TEM1657 compound for the treatment of psoriasis   TEM1657 is a drug candidate discovered and optimized by Plant Advanced Technologies (PAT), a French Biotech company based in Vandœuvre-lès-Nancy. The preclinical studies perfomed with TEM1657 in ETAP-Lab's model of psoriasis in mice have demonstrated a similar efficacy to that of corticosteroids, the current reference of the market, but without their undesirable side effects. The results have been presented for the first time at the

  Atopic dermatitis is a chronic allergic disease of the skin characterized by pruritus and eczematous skin lesions. It affects about 10 million people in the world, leading to a significant reduction in quality of life, and its incidence is continuously increasing in westernized countries. The pathogenesis of atopic dermatitis is unknown, but the disease seems to be correlated with specific immune and inflammatory mechanisms and keratinocytes, which are the main type of epidermal cells, play a key role in the

ETAP-Lab (Dr Nicolas Violle, President and CEO) is a well-established CRO, with more than 25 years of market knowledge. ESRP is the offshoot of the highly-recognized INSERM unit “Physiopathology and Imaging of Neurological Disorders” (PhIND; Pr. Denis Vivien, Head of the unit). The new platform STROK@LLIANCE is fully dedicated to preclinical stroke in order to address mechanisms, diagnostics and therapeutics in stroke. STROK@LLIANCE manages projects in the field of stroke for the pharmaceutical industry with high-skilled specialists ensuring expertise and creativity to provide high-level animal studies in a

Publication of a new article written by ETAP-Lab evaluating the effects of green algae  on anxiety and depression : “Evaluation of the antidepressant- and anxiolytic-like effects of a hydrophilic extract from the green seaweed Ulva sp. in rats”, Nutr Neurosci. 2017 Jan 19:1-9. PMID:28102110

Launch of STROK@LLIANCE, the new preclinical platform resulting from the alliance of the academic Experimental Stroke Research Platform (ESRP) and the well-established CRO ETAP-Lab. For half a day, neurologists, neuroradiologists, neurosurgeons, researchers, specialists in preclinical and clinical trials, will give you an overview of stroke etiology, current acute management practices and animal modeling. Next, they will discuss with you during a debate: "The transition from preclinical drug to clinical drug for stroke: What are the essential information for clinicians about pharmacology issues?"